Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors
摘要:
A series of novel 2,3-diaryl-2-cyclobuten-1-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-I and COX-2. 4,4-Dimethyl-2-phenyl-3- [4-(methylsulfonyl)phenyl]cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (ED(50) = 2.4 mg/kg) in the rat paw edema model. Copyright (C) 1996 Elsevier Science Ltd
Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
申请人:Merck Frosst Canada, Inc.
公开号:US05817700A1
公开(公告)日:1998-10-06
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
[EN] BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS<br/>[FR] DERIVES BISARYLCYCLOBUTENE COMME INHIBITEURS DE LA CYCLO-OXYGENASE
申请人:MERCK FROSST CANADA INC.
公开号:WO1997036863A1
公开(公告)日:1997-10-09
(EN) The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).(FR) L'invention concerne le nouveau composé de la formule (I), qui est utile pour le traitement des maladies associées à la cyclo-oxygénase-2. L'invention concerne, également, des compositions pharmaceutiques pour le traitement de maladies associées à la cyclo-oxygénase-2 contenant les composés de la formule (I).